New trials, publications, preprints and grants on this target, month by month.
Trial
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
B cells and the therapeutic index of checkpoint blockade.
2 Nov 2026· The Journal of clinical investigation· PUBMED
Publication
Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Trial
Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
1 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.
1 Nov 2026· Hematological oncology· PUBMED
Trial
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
30 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology.
23 Oct 2026· Mucosal immunology· PUBMED
Publication
PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study.
22 Oct 2026· Frontiers in oncology· PUBMED
Publication
The role of interleukins and immunological parameters in patients with colon cancer: an optical insight.
22 Oct 2026· Lasers in medical science· PUBMED
Trial
A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
20 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
CTLA-4/PD-1, LAG-3, and TIGIT Inhibitors: Emerging Drug Targets and Combination Strategies in Hepatocellular Carcinoma.
20 Oct 2026· Current cancer drug targets· PUBMED
Publication
Association of immune checkpoint-related polymorphisms in PD-1, PD-L1, and CTLA-4 genes with susceptibility to genitourinary cancer: a meta-analysis.
15 Oct 2026· Immunologic research· PUBMED
Publication
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial.
6 Oct 2026· Nature communications· PUBMED
Trial
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors
3 Oct 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Preprint
Engineered CTLA-4 targeting chimeras for targeted protein degradation and immune synapse reprogramming.
2 Oct 2026· bioRxiv : the preprint server for biology· PUBMED
Trial
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
1 Oct 2026· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publication
Anti-PD-1/CTLA-4 bispecific antibody-based combination therapy for cervical cancer: a multicenter study with biomarker analysis.
1 Oct 2026· Frontiers in immunology· PUBMED
Publication
Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies.
1 Oct 2026· Frontiers in immunology· PUBMED
Trial
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
30 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Oncolytic virus VT1092M synergizes with immune checkpoint inhibitors against intraperitoneal metastases of colorectal cancer.
30 Sept 2026· Frontiers in immunology· PUBMED
Publication
Impact of obesity on LAG-3 and CTLA-4 expression in CD4+ T cells from lymph nodes of sarcoidosis patients.
25 Sept 2026· Immunobiology· PUBMED
Publication
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
15 Sept 2026· Cancer research· PUBMED
Trial
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
14 Sept 2026· PHASE2 · RECRUITING· CTGOV
Publication
Quantitative Systems Pharmacology Model Predicts Enhanced Antitumor Efficacy of Combined Cytotoxic T‑Lymphocyte-Associated Protein 4 (CTLA-4) and Programmed Cell Death Protein 1 (PD-1) Blockade in a Syngeneic Mouse Model of Breast Cancer.
10 Sept 2026· ACS pharmacology & translational science· PUBMED
Trial
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
9 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.
5 Sept 2026· Nature communications· PUBMED
Publication
Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy.
4 Sept 2026· Journal for immunotherapy of cancer· PUBMED
Publication
Comparative Analysis of the Immune Profiles of Women and Men With Hepatocellular Carcinoma.
1 Sept 2026· Cancer medicine· PUBMED